Xolremdi (mavorixafor, oral CXCR4 antagonist for WHIM syndrome)
Named-patient access overview. Xolremdi is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Xolremdi
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Xolremdi
Xolremdi (mavorixafor) is an oral, once-daily small-molecule antagonist of the CXCR4 chemokine receptor, developed by X4 Pharmaceuticals. It is approved by the US FDA for patients aged 12 years and older with WHIM syndrome, the rare inherited primary immunodeficiency defined by warts, hypogammaglobulinemia, recurrent infections, and myelokathexis (the retention of mature neutrophils in the bone marrow).
The biology of WHIM syndrome is driven by gain-of-function mutations in CXCR4 that trap mature neutrophils and lymphocytes in the bone marrow instead of releasing them into the peripheral circulation. By antagonizing CXCR4, mavorixafor blocks that retention signal and mobilizes neutrophils and lymphocytes into the bloodstream, addressing the underlying mechanism of the recurrent infections that define the disease.
For international patients, Xolremdi is sourced by Reserve Meds from a US-licensed pharmaceutical wholesale partner with full serial traceability and may be accessible via Named Patient Program or personal-import pathways depending on destination country.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Xolremdi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Xolremdi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Xolremdi is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list mavorixafor as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Xolremdi in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Xolremdi
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Xolremdi if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Xolremdi for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Xolremdi through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Xolremdi. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Xolremdi through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Xolremdi to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Xolremdi to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Xolremdi cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Xolremdi?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.